|Bid||0.310 x 0|
|Ask||0.320 x 0|
|Day's Range||0.305 - 0.320|
|52 Week Range||0.140 - 0.600|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.26|
Immuron Limited (ASX:IMC) (IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is today pleased to announce the successful completion of its colitis preclinical program at the University of Zürich, Switzerland. Immuron is pleased to report that oral administration of IMM-124E was successfully able to treat mice with immunologically induced colitis. In contrast to the results reported in April 2017 using an acute colitis model the latest results were generated in the T cell transfer model which utilizes immunodeficient mice which are deficient in functional B and T lymphocytes.
MELBOURNE, Australia, April 23, 2018-- Immuron Limited, Australian microbiome biopharmaceutical company focused on developing and commercialising orally delivered targeted polyclonal antibodies for the ...
US Travelan ® sales continue an upward trend with a 95% increase in the Third Quarter of 2018 compared to the same period last year. YTD US sales climbed to$ AUD501K, representing a strong 178% increase ...
U.S. exchanges are set to record their busiest year for IPOs from Asian firms since 2010 and may sustain the pace in 2018, as startups from Taiwan, Singapore, Indonesia and Vietnam join a flurry of Chinese firms that have already listed in the country. Chinese issuers have dominated U.S. IPO activity for several years, but Nasdaq and rival New York Stock Exchange (NYSE) have been increasingly targeting firms from fast-growing Southeast Asian economies and startups from Japan and Australia to counter their dependence on mainland companies.